Trading was heavy with 42K shares changing hands on Tuesday. Overall, volume was up 207.18% over the stocks normal daily volume.
Short traders are more bearish on Immucell Cp lately as evidenced by the change in short interest. The stock recorded a rise in short interest of 42.94% as of the latest report on October 13, 2017. Short interest grew from 10,691 to 15,282 over that timeframe. The short-interest ratio decreased to 2.0 and the short interest percentage is 0.00% as of October 13.
Here are a few substantial investment firms who have updated their positions. As of the end of the quarter Tower Research Capital LLC (trc) had sold a total of 478 shares trimming its stake by 89.0%. The value of the company’s investment in Immucell Cp went from $3,000 to $0 a change of 100.0% for the reporting period. Ubs Group Ag bolstered its ownership by buying 1,143 shares an increase of 757.0% from 03/31/2017 to 06/30/2017. Ubs Group Ag controls 1,294 shares with a value of $9,000. The value of the position overall is up by 800.0%.
As of quarter end Essex Investment Management CO LLC had acquired 16,249 shares growing its position 155.3%. The value of the total investment in Immucell Cp increased from $77,000 to $174,000 a change of $97,000 quarter over quarter. As of quarter end Wells Fargo & Company/mn had acquired a total of 1,701 shares growing its holdings by 7.4%. The value in dollars decreased from $169,000 to $161,000 decreasing 4.7% quarter to quarter.
The company is now up by 1.22% percent from yesterday’s close. The most current P/E ratio is 649.07 and market cap is 45.97M. As of the latest earnings report the EPS was $0.01 with 5.05M shares outstanding.
ImmuCell Corporation, launched on February 9, 1987, is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Business’s lead product, First Defense, is manufactured from cows’ colostrum (the milk that a cow produces immediately after giving birth) utilizing its vaccine and milk protein purification technologies. The Business’s Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. The Company also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. The Business’s product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows..